Andrew McConaghie
Senior Writer
Andrew writes on a range of topics across biopharma sector R&D and commercial issues, from new biotech start-ups to COVID-19 vaccines and new cancer, cell and gene therapies.
Latest From Andrew McConaghie
EHA Preview: ASCO Overlap Gives Smaller Companies Chance To Shine
Cargo Therapeutics has got an early boost from its abstract to be presented the European meeting, while Shattuck has suffered on safety doubts for its CD47 inhibitor.
EHA Preview: Agios Takes Spotlight In Thalassemia
The company expects to have data from transfusion-dependent and non-transfusion dependent patients this year, with a potential expanded US approval in 2025 for Pyrukynd.
Takeda Gets A Try-Before-You-Buy Option In Alzheimer’s Immunotherapy
The Japanese company will await imaging results to see if AC Immune’s candidate ACI-24.060 can help prevent or remove plaques before finalizing the deal.
MacroGenics Plunges On Prostate Cancer ADC Safety Concerns
A more than 70% stock slide shows that investors are concerned about three as-yet unexplained deaths in a Phase II study of the US firm’s lead candidate.
Hibernating Squirrels And Exercise In A Pill: The Next Wave of Cardiometabolic Therapies
Early-stage companies pioneering new modalities discussed the future of cardiometabolic therapy and partnering with big pharma at the LSX conference in London.
BioNTech Ramps Up Spending To Launch 10 Pivotal Cancer Studies In 2024
As COVID-19 vaccine sales decline, the company is investing billions in a diverse oncology pipeline including antibody drug conjugates, immunotherapy and cancer vaccines